Clinical Studies and Trials
Among the 204 identified CSF proteins, 13 showed significant changes in A-T patients versus control samples.
Two laboratory markers of oxidative stress improved when participants took both alpha-lipoic acid and nicotinamide.
This trial assessed the safety and efficacy of the EryDex System to treat neurological symptoms associated with A-T.
Goals of this study are to develop non-invasive markers that will lessen the impact of swallowing dysfunction.
This study aimed to determine if inositol has therapeutic benefit for total lymphocyte count or ataxia.
IntraBio, Inc. is studying the effects of N-Acetyl-L-Leucine on A-T.
This study seeks to develop sensitive, automated and objective means of measuring neurological disease severity.
- « Previous
- 1
- 2